Efficacy and safety of radiofrequency, microwave and laser ablation for treating papillary thyroid microcarcinoma: a systematic review and meta-analysis. (1st January 2019)

• Record Type: Journal Article
• Authors: Tong, Mengying; Li, Shuang; Li, Yulong; Li, Ying; Feng, Yue; Che, Ying
• Is Part Of: International journal of hyperthermia. Volume 36:Number 1(2019)
• Page Start: 1277
• Page End: 1285
• Publication Date: 2019-01-01
• Subjects: Papillary thyroid microcarcinoma -- radiofrequency ablation -- microwave ablation -- laser ablation -- ultrasound; Thermotherapy -- Periodicals; 615.832
• DOI: 10.1080/02656736.2019.1700559
• Languages: English
• ISSNs: 0265-6736

Abstract

Abstract: Background: To evaluate the efficacy and safety of radiofrequency ablation (RFA), microwave ablation (MWA) and laser ablation (LA) for treating papillary thyroid microcarcinoma (PTMC). Materials and methods: PUBMED and EMBASE were searched for studies on the efficacy and safety of RFA, MWA and LA for treating PTMC. The standard mean difference of the tumor volume before and after therapy and the proportion of complete disappearance, local recurrence, distant metastasis and complications were assessed using both fixed or random-effects modeling. Heterogeneity among studies was determined using the Q statistic for the pooled estimates and the inconsistency index I 2 . Results: A total of 12 eligible studies, including a sample size of 1187 patients and 1284 PTMCs, were used. RFA, MWA and LA all showed a significant reduction in tumor volume of PTMCs ( p < 0.05). Though MWA demonstrated superior efficacy over the other two therapies for volume reduction, the differences were not statistically significant. Additionally, the pooled proportion of complete disappearance after RFA was the highest (76.2%), and the pooled proportion of recurrence for RFA was the lowest (0.01%) among the three therapeutic methods, but no significant difference was detected. There was no event of distant metastasis during the follow-up in all of these studies. Few major complications were encountered; the pooled proportion of complications for RFA (1.73%), MWA (6.0%) and LA (0.92%) was low, revealing no significant differences ( p > 0.05). Conclusion: RFA, MWA and LA are acceptable treatments to manage PTMCs in terms of efficacy and safety for non-surgical candidates.